Sumitomo Pharma Co., Ltd.
4506
Clasificación en acciones
#3218
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Precio por acción
$12.27
Capitalización bursátil
$5.51B
Cambio (1 día)
2.20%
Cambio (1 año)
6.72%
País
JP
Comercio Sumitomo Pharma Co., Ltd. (4506)
Categoría
Healthcare
Margen Operativo de Sumitomo Pharma Co., Ltd. (4506)
Margen Operativo al October 2026 TTM: 10.05%
Según los informes financieros más recientes y el precio de las acciones de Sumitomo Pharma Co., Ltd., el margen operativo actual (TTM) es 10.05%. Al final de 2024, el margen operativo era -112.60%.
Historial de Margen Operativo de Sumitomo Pharma Co., Ltd. desde 2005 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 10.05% | 39.20% |
| 2025 | 7.22% | -106.41% |
| 2024 | -112.60% | 712.41% |
| 2023 | -13.86% | -228.81% |
| 2022 | 10.76% | -22.03% |
| 2021 | 13.80% | -19.95% |
| 2020 | 17.24% | 36.83% |
| 2019 | 12.60% | -33.30% |
| 2018 | 18.89% | 47.35% |
| 2017 | 12.82% | 39.96% |
| 2016 | 9.16% | 46.09% |
| 2015 | 6.27% | -42.32% |
| 2014 | 10.87% | 50.97% |
| 2013 | 7.20% | 23.71% |
| 2012 | 5.82% | -28.68% |
| 2011 | 8.16% | -32.11% |
| 2010 | 12.02% | 1.86% |
| 2009 | 11.80% | -21.75% |
| 2008 | 15.08% | -13.53% |
| 2007 | 17.44% | 48.43% |
| 2006 | 11.75% | 77.49% |
| 2005 | 6.62% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -97.72% |
IN
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.